Remsima records 73% and Remsima SC 14%
Becomes No. 1 in prescription similar drug market,
Celltrion logo. Provided by Celltrion,
, ‘[Seoul Economy]’,
,
, ‘Celltrion maintained its No. 1 prescription rank in the UK, one of the major five countries in Europe (EU5), with a market share of 87% for Infliximab.’,
,
, ‘According to IQVIA, a pharmaceutical market research firm, the Remsima product group, with Infliximab as its active ingredient, maintained its No. 1 rank in the UK market for Infliximab, recording an 87% market share in the first quarter of this year. Among them, Remsima SC accounted for 14%. Celltrion’s UK subsidiary plans to exceed a 20% market share by the end of the year by continuing its growth trajectory with Remsima SC alone.’,
,
, ‘The UK accounts for about 16% of the Infliximab market size in Europe. The UK government has created a favorable institutional environment by supporting the expansion of biosimilar prescriptions with competitive prices. However, in order to supply pharmaceuticals stably, it is known that successful bids from the National Health Service (NHS) in the four administrative regions are necessary, making sales activities in the field crucial.’,
,
, ‘Regarding the increase in prescriptions of Remsima SC, Celltrion explained, “The UK subsidiary focused on increasing patient preference through expanding sales force for Remsima SC and providing patient support programs such as ‘Celltrion Connect’ for delivery and tailored medical staff visit education services.”‘,
,
, ‘Growth has also continued in other product groups. Bevacizumab biosimilar for the treatment of metastatic colorectal cancer and breast cancer, called ‘Begezma’ (active ingredient: Bevacizumab), climbed to the top rank for Bevacizumab biosimilar prescriptions just one year after its launch in 2022, with a 32% market share, an 8-point increase from the previous quarter.’,
,
, ‘Trastuzumab biosimilar for the treatment of hematologic cancers, called ‘Truxima’ (active ingredient: Rituximab), showed a high market share of 36% compared to the original drug. Uplizna (active ingredient: Adalimumab), a treatment for autoimmune diseases, recorded a 7% market share, a 3-point increase from the previous quarter. Celltrion plans to secure a market share of over 20% for Uplizna by the end of the year as a new 20mg product for pediatric patients has been added.’,
,
, ‘Celltrion’s UK subsidiary plans to continue its success with subsequent products such as Stelara biosimilar ‘Stecima’ (active ingredient: Ustekinumab) and Jolera biosimilar ‘Omliclo’ (active ingredient: Omalizumab), which have recently obtained marketing authorization in Europe. Kim Dong-sik, head of Celltrion’s UK subsidiary, said, “We will make our best efforts to solidify our position as a global top-tier biosimilar company by actively utilizing the trust relationships and tailored market entry know-how accumulated in the medical field, and we will continue to contribute to the UK healthcare environment.”‘,
,
,